Saudi Arabia’s General Authority for Military Industries Announces a Fully Integrated Defense Show Starting March 2022
17.7.2020 00:05:00 EEST | Business Wire | Press release
Today the Kingdom of Saudi Arabia’s General Authority for Military Industries (GAMI) announced the launch of ‘World Defense Show’. The show will take center stage in the global defense show circuit, offering exhibitors and visitors the opportunity to participate in Saudi Arabia’s first truly integrated defense show.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716006046/en/
His Excellency Ahmad Al Ohali, Governor of GAMI (Photo: AETOSWire)
Founded by GAMI, World Defense Show is focused on interoperability across air, land, sea, security innovative defense technologies and satellite defense systems. The inaugural event is scheduled to take place between 6th and 9th March 2022 and will then be held biennially in Saudi Arabia’s capital, Riyadh.
Speaking at a virtual press conference attended by international defense companies, GAMI’s Governor, His Excellency Ahmad Al Ohali stated: “As Technology is accelerating the rate at which the global defense industry is evolving, defense considerations are becoming increasingly complex. There is a need for a platform, which enables the defense community to convene and collectively consider the great opportunities and challenges that are facing us all. This is why we are launching World Defense Show, an innovative platform showcasing, through both live and virtual demonstrations, the possibilities that interoperability can provide across all five defense domains: Air, Land, Sea, Security and Satellite.”
He added, “There is no better place than Saudi Arabia to organize a defense event at this scale. A G20 country, the Kingdom is one of the world’s biggest defense spenders with a strategic location at the center of three continents, making it an ideal hub for defense trade and innovation. Saudi Arabia’s vision to localize 50% of its multi-billion-dollar defense expenditure by 2030 also presents massive opportunities to global industry OEMs and investors.”
GAMI has recruited a team of international experts to organize and run event operations.
Shaun Ormrod, Chief Executive Officer, World Defense Show, said: “Today’s launch of World Defense Show marks an exciting inflection point for the defense industry and a step forward in the ambition and scale of a defense trade show. Through World Defense Show we will demonstrate why Saudi Arabia is critical to the defense industry’s future. The platform will enable access to dedicated programs that support Saudi Arabia’s local businesses, it will leverage investment opportunities and encourage a new generation to aspire to work in the defense industry.” Mr. Ormrod is the former CEO of Farnborough Airshow with over 20 years of industry trade show expertise.
Over four days, World Defense Show will showcase comprehensive and interactive displays of integrated defense technology solutions, alongside conferences and thought leadership seminars focused on the next generation of defense. The show’s venue, estimated to accommodate 80,000 square meters of exhibition, hospitality and outdoor area, will feature demonstration facilities and virtual technological capabilities to showcase every defense domain on an unprecedented scale.
Video News Release embed and download link here
About World Defense Show
World Defense Show is a display and demonstration of integrated and innovation-driven defense solutions, set to serve as the global stage for defense interoperability. The inaugural World Defense Show will take place biannually starting March 2022 in Riyadh - Saudi Arabia, to showcase the latest in interoperable defense solutions. The event will be held in the presence of Saudi Arabia’s key leadership, international delegations and prominent industry decision makers from around the world.
About General Authority for Military Industries
The founder of World Defense Show, Saudi Arabia’s General Authority for Military Industries, is the regulator, enabler and licensor for the kingdom’s military industry. GAMI is responsible for domestic defense sector development in line with the national commitment to localize 50% of military manufacturing by 2030.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716006046/en/
Contact information
Yara Abifaker, +971544285342
yara.abifaker@finsbury.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom